Technology: Electroceutical neuromodulation therapy
CEO: Milton M. Morris
NeuSpera leverages exclusively licensed mid-field powering techniques to engineer miniaturized injectable neuromodulation technologies (aka electroceuticals). NeuSpera’s implantable module is more than 100 times smaller than other neuromodulation devices and may substantially reduce implant procedure complexity, time, patient complication and post-surgical pain. The idea is that miniature devices can modulate the electrical impulses in the body, triggering biochemical processes more typically manipulated via biopharmaceuticals. The end game is to replace drug therapies by inducing the body to heal itself of major illnesses that could include diabetes, asthma, hypertension, arthritis, pain and even cancer. NeuSpera Medical is committed to bringing forward implantable medical device technology that will improve lives of patients battling with chronic illness. The company raised $8 million in 2016.